Diabetes mellitus is one of the major public health problems worldwide. Considerable recent evidence suggests that the cellular reduction-oxidation (redox) imbalance leads to oxidative stress and subsequent occurrence and development of diabetes and related complications by regulating certain signaling pathways involved in β-cell dysfunction and insulin resistance. Reactive oxide species (ROS) can also directly oxidize certain proteins (defined as redox modification) involved in the diabetes process. There are a number of potential problems in the clinical application of antioxidant therapies including poor solubility, storage instability and nonselectivity of antioxidants. Novel antioxidant delivery systems may overcome pharmacokinetic and stability problem and improve the selectivity of scavenging ROS. We have therefore focused on the role of oxidative stress and antioxidative therapies in the pathogenesis of diabetes mellitus. Precise therapeutic interventions against ROS and downstream targets are now possible and provide important new insights into the treatment of diabetes.

糖尿病是全球主要的公共卫生问题之一。近期大量证据表明，通过调节某些与β细胞功能障碍和胰岛素抵抗有关的信号通路，细胞氧化还原（氧化还原）失衡会导致氧化应激以及随后的糖尿病和相关并发症的发生和发展。活性氧化物（ROS）也可以直接氧化涉及糖尿病过程的某些蛋白质（定义为氧化还原修饰）。抗氧化剂疗法的临床应用中存在许多潜在的问题，包括不良的溶解性，抗氧化剂的储存不稳定性和非选择性。新型抗氧化剂输送系统可以克服药代动力学和稳定性问题，并提高清除ROS的选择性。因此，我们专注于氧化应激和抗氧化疗法在糖尿病发病机理中的作用。现在可以对ROS和下游靶点进行精确的治疗干预，并为糖尿病的治疗提供重要的新见解。